Results 31 to 40 of about 51,607 (296)

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Haematologica, 2020
Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem cell transplant (auto-PBSCT) predicts progression-free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL).
M. Kersten, J. Driessen, J. Zijlstra, W. Plattel, F. Morschhauser, P. Lugtenburg, P. Brice, M. Hutchings, T. Gastinne, Roberto D. K. Liu, C. Burggraaff, M. Nijland, S. Tonino, A. Arens, R. Valkema, H. van Tinteren, M. Lopez-Yurda, A. Diepstra, D. de Jong, A. Hagenbeek   +19 more
semanticscholar   +1 more source

Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

BMC Cancer, 2018
Background The addition of high-dose cytarabine to the treatment of mantle cell lymphoma (MCL) has significantly prolonged survival of patients, but relapses are common and are normally associated with increased resistance.
Catja Freiburghaus, Venera Kuci Emruli, Angelica Johansson, Christian Winther Eskelund, Kirsten Grønbæk, Roger Olsson, Fredrik Ek, Mats Jerkeman, Sara Ek   +8 more
doaj   +1 more source

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Leukemia, 2018
Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or ...
J. Cortes, F. Heidel, A. Hellmann, W. Fiedler, B. Smith, T. Robak, P. Montesinos, D. Pollyea, P. Desjardins, O. Ottmann, W. Ma, M. N. Shaik, A. Laird, M. Zeremski, A. O’Connell, G. Chan, M. Heuser   +16 more
semanticscholar   +1 more source

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia.

Future Oncology, 2020
Patients with refractory or relapsed acute myeloid leukemia (R/R AML) have a poor prognosis, with a high unmet medical need. Idasanutlin is a small-molecule inhibitor of MDM2, a negative regulator of tumor suppressor p53.
P. Montesinos, Benjamin M. Beckermann, O. Catalani, J. Esteve, Katia Gamel, M. Konopleva, G. Martinelli, Annabelle Monnet, C. Papayannidis, Aaron Park, C. Récher, R. Rodríguez-Veiga, C. Röllig, N. Vey, A. Wei, S. Yoon, P. Fenaux   +16 more
semanticscholar   +1 more source

EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.

The Oncologist, 2020
On June 28, 2018, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vyxeos, intended for the treatment of acute myeloid leukemia (AML).
Kyriaki Tzogani, K. Penttilä, Tuomo Lapveteläinen, R. Hemmings, J. Koenig, J. Freire, Silva Márcia, S. Cole, P. Coppola, Beatriz Flores, Y. Barbáchano, Silvia Domingo Roige, F. Pignatti   +12 more
semanticscholar   +1 more source

Invasive Fungal Disease Associated With Targeted Agents for Acute Myeloid Leukaemia: A Systematic Review. [PDF]

EJHaem
ABSTRACT Objective To examine the incidence of invasive fungal disease (IFD) in patients receiving targeted agents for acute myeloid leukaemia (AML). Methods Literature for this systematic review was identified through a PubMed search in April 2024, using AML, IFD and targeted therapy terms.
Agrawal S, Bapat A, Eades CP, Gandhi S.
europepmc   +2 more sources

Cytarabine and clofarabine after high‐dose cytarabine in relapsed or refractory AML patients [PDF]

American Journal of Hematology, 2012
AbstractClofarabine has been shown to be effective in AML patients, either as single agent or, mainly, in association with intermediate dose cytarabine. Based on these reports, we conducted a preliminary study combining clofarabine and intermediate dose cytarabine in AML patients who relapsed or failed to respond to at least two induction therapies. We
Scappini B, Gianfaldoni G, Caracciolo F, Mannelli F, Biagiotti C, Romani C, Pogliani EM, Simonetti F, Borin L, Fanci R, Cutini I, Longo G, Susini MC, Angelucci E, Bosi A   +14 more
openaire   +4 more sources

Mutant C/EBPα p30 alleviates immunosuppression of CD8+ T cells by inhibiting autophagy‐associated secretion of IL‐1β in AML

Cell Proliferation, Volume 55, Issue 12, December 2022., 2022
Mp30 suppresses autophagy‐associated IL‐β secretion, which ultimately alleviates the immunosuppression of CD8+ T cells in the microenvironment, contributing to favourable prognosis of AML patients. Abstract Objectives Mutant C/EBPα p30 (mp30), the product of C/EBPα double mutations (DM), lacks transactivation domain 1 and has C‐terminal loss‐of ...
Jun‐Dan Wang, Jue‐Qiong Xu, Xue‐Ning Zhang, Ze‐Wei Huang, Ling‐Ling Liu, Ling Zhang, Xin‐Xing Lei, Man‐Jie Xue, Jian‐Yu Weng, Zi‐Jie Long   +9 more
wiley   +1 more source

The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes

Haematologica, 2019
Although cytarabine has been widely considered as one of the chemotherapy drugs for high-risk myelodysplastic syndromes (MDS), the overall response rate is only approximately 20-30%.
Peipei Lin, Yanling Ren, Xiaomei Yan, Yingwan Luo, Hua Zhang, Meenu Kesarwani, Jiachen Bu, Di Zhan, Yile Zhou, Yuting Tang, Shuanghong Zhu, Weilai Xu, Xinping Zhou, Chen Mei, Liya Ma, Li Ye, Chao Hu, Mohammad Azam, Wei Ding, Jie Jin, Gang Huang, Hongyan Tong   +21 more
doaj   +1 more source

FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

Clinical Cancer Research, 2018
On August 3, 2017, the FDA granted regular approval to Vyxeos (also known as CPX-351; Jazz Pharmaceuticals), a liposomal formulation of daunorubicin and cytarabine in a fixed combination, for the treatment of adults with newly diagnosed therapy-related ...
A. Krauss, Xin Gao, Liang Li, M. Manning, Paresma Patel, W. Fu, Kumar G. Janoria, G. Gieser, David A. Bateman, D. Przepiorka, Y. Shen, S. Shord, Christopher M. Sheth, A. Banerjee, Jiang Liu, Kirsten B. Goldberg, A. Farrell, G. Blumenthal, R. Pazdur   +18 more
semanticscholar   +1 more source